

| Número de catálogo | HW342026 |
|---|---|
| Descripción |
Pogalizumab (HW342026) is a research-grade recombinant antibody targeting CD134. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Reactividad de especies | Human |
| Aplicaciones | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Especie huésped | Human |
| Clonalidad | Monoclonal |
| Isotipo | IgG1-kappa |
| Objetivo | ACT35 antigen, CD134, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, TNFRSF4, TXGP1L, Tumor necrosis factor receptor superfamily member 4 |
| Nivel de endotoxinas | < 10 EU/mg |
| Pureza | >95% as determined by SDS-PAGE. |
| Purificación | Protein A/G purified from cell culture supernatant. |
| Número de acceso | P43489 |
| Forma | Liquid |
| Buffer de almacenamiento | 0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote. |
| Estabilidad y almacenamiento | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | Vonlerolizumab, MOXR-0916, MOXR0916, RG-7888, RO7021608, 1638935-72-4 |
| Fondo | Tumor necrosis factor receptor superfamily member 4 (CD134/OX40) is a ~29 kDa protein. Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity. |
| Nota | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Anti-LASV GPC Recombinant Antibody (Fab 37.7) (VK453013) |

SDS-PAGE for Research Grade Pogalizumab.




Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.
Correo: [email protected]


+86-027-65523339
Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский